CorMedix (NASDAQ:CRMD – Get Free Report) issued its earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07), FiscalAI reports. The business had revenue of $54.52 million for the quarter, compared to analyst estimates of $51.76 million. CorMedix had a net margin of 40.49% and a return on equity of 40.52%.
Here are the key takeaways from CorMedix’s conference call:
- CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets, which management expects to add approximately $125 million–$150 million in 2027 revenue and generate $45 million–$60 million in annualized cost synergies by the end of 2027. The deal is expected to be immediately accretive to earnings and free cash flow, subject to closing conditions.
- DefenCath utilization at large dialysis customers largely held steady after the post-TDAPA reimbursement change, and management expects the 2027 add-on payment to remain above the current $2.37 rate. However, the quarterly payment framework and unresolved customer pricing and Medicare Advantage arrangements leave the company unable to provide 2027 DefenCath guidance yet.
- Third-quarter revenue was $54.5 million and adjusted EBITDA was $3.1 million; DefenCath sales were $17.2 million, including a $5 million favorable adjustment to sales allowances. CorMedix maintained its 2026 revenue outlook at $325 million–$345 million and narrowed adjusted EBITDA guidance to $130 million–$140 million, while ending the quarter with $355.2 million in cash.
- The FDA accepted REZZAYO’s supplemental application for prophylaxis with priority review and a target decision in the first quarter of 2027. CorMedix is preparing for a potential launch in the second half of 2027 if approved.
- Enrollment in the phase III TPN study for DefenCath remains meaningfully behind schedule despite added sites and a protocol amendment. Management is evaluating alternative FDA pathways and expects to decide on the study strategy before its next quarterly update.
CorMedix Price Performance
CRMD stock traded down $0.00 during trading on Friday, hitting $4.84. 727,845 shares of the stock traded hands, compared to its average volume of 1,615,619. CorMedix has a one year low of $4.72 and a one year high of $13.02. The stock has a market cap of $377.00 million, a price-to-earnings ratio of 2.25, a P/E/G ratio of 0.99 and a beta of 1.48. The company has a 50 day simple moving average of $7.25 and a 200 day simple moving average of $7.58. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31.
Wall Street Analysts Forecast Growth
CRMD has been the subject of a number of analyst reports. UBS Group set a $19.00 price target on shares of CorMedix in a research note on Tuesday. Weiss Ratings lowered CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Needham & Company LLC increased their target price on CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup reissued a “market outperform” rating on shares of CorMedix in a report on Tuesday. Finally, Royal Bank Of Canada raised their target price on CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.22.
View Our Latest Stock Analysis on CRMD
Key Headlines Impacting CorMedix
These are some of the CRMD headlines that stood out recently:
- Positive Sentiment: Oppenheimer reaffirmed its “outperform” rating and kept a $13 price target, although it cut the target from $15. The target still implies substantial upside from recent trading levels. Oppenheimer rating
- Positive Sentiment: CorMedix reported Q3 revenue of $54.5 million, above analysts’ $51.8 million estimate, and maintained its 2026 revenue outlook while narrowing its adjusted EBITDA guidance. Q3 results and business update
- Negative Sentiment: Despite the revenue beat, reported EPS of a $0.19 loss missed the consensus estimate of a $0.12 loss. Coverage also pointed to DefenCath pricing pressure, a concern for sales and likely a key reason shares were under pressure. Q3 estimates and pricing pressure
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Read More
- Five stocks we like better than CorMedix
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
